Triumeq PD (abacavir/dolutegravir/lamivudine) – New formulation approval
March 30, 2022 - ViiV Healthcare announced the FDA approval of Triumeq PD(abacavir/dolutegravir/lamivudine) tablets for oral suspension, for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg.
Top